Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NILK-2301 in Low Tumor Volume Colorectal Cancer
NCT06663839Phase 1Recruiting
- Sponsor
- Lightchain Bioscience
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NILK-2301 in colorectal cancer (CRC), sponsored by Lightchain Bioscience. Primary endpoints: Dose Limiting Toxicity up to 12 months, Non-Tolerated Dose up to 12 months and 2 more. Started Apr 2024; status: recruiting.
02
Drugs
NILK-2301
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06663839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663839.